<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35477864</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-3288</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Gut</Title><ISOAbbreviation>Gut</ISOAbbreviation></Journal><ArticleTitle>Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic.</ArticleTitle><Pagination><StartPage>1426</StartPage><EndPage>1439</EndPage><MedlinePgn>1426-1439</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/gutjnl-2021-326784</ELocationID><Abstract><AbstractText>The COVID-19 pandemic has raised considerable concerns that patients with inflammatory bowel disease (IBD), particularly those treated with immunosuppressive therapies, may have an increased risk of SARS-CoV-2 acquisition, develop worse outcomes following COVID-19, and have suboptimal vaccine response compared with the general population. In this review, we summarise data on the risk of COVID-19 and associated outcomes, and latest guidance on SARS-CoV-2 vaccines in patients with IBD. Emerging evidence suggests that commonly used medications for IBD, such as corticosteroids but not biologicals, were associated with adverse outcomes to COVID-19. There has been no increased risk of de novo, or delayed, IBD diagnoses, however, an overall decrease in endoscopy procedures has led to a rise in the number of missed endoscopic-detected cancers during the pandemic. The impact of IBD medication on vaccine response has been a research priority recently. Data suggest that patients with IBD treated with antitumour necrosis factor (TNF) medications had attenuated humoral responses to SARS-CoV-2 vaccines, and more rapid antibody decay, compared with non-anti-TNF-treated patients. Reassuringly, rates of breakthrough infections and hospitalisations in all patients who received vaccines, irrespective of IBD treatment, remained low. International guidelines recommend that all patients with IBD treated with immunosuppressive therapies should receive, at any point during their treatment cycle, three primary doses of SARS-CoV-2 vaccines with a further booster dose as soon as possible. Future research should focus on our understanding of the rate of antibody decay in biological-treated patients, which patients require additional doses of SARS-CoV-2 vaccine, the long-term risks of COVID-19 on IBD disease course and activity, and the potential risk of long COVID-19 in patients with IBD.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Lin</LastName><ForeName>Simeng</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4201-4879</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lau</LastName><ForeName>Louis Hs</ForeName><Initials>LH</Initials><Identifier Source="ORCID">0000-0002-4163-4531</Identifier><AffiliationInfo><Affiliation>Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chanchlani</LastName><ForeName>Neil</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-0207-6706</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kennedy</LastName><ForeName>Nicholas A</ForeName><Initials>NA</Initials><Identifier Source="ORCID">0000-0003-4368-1961</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Siew C</ForeName><Initials>SC</Initials><Identifier Source="ORCID">0000-0002-6850-4454</Identifier><AffiliationInfo><Affiliation>Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China siewchienng@cuhk.edu.hk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Microbiota I-Center (MagIC), Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Gut</MedlineTA><NlmUniqueID>2985108R</NlmUniqueID><ISSNLinking>0017-5749</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015212" MajorTopicYN="Y">Inflammatory Bowel Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Crohn's disease</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antibody</Keyword><Keyword MajorTopicYN="N">immune response</Keyword><Keyword MajorTopicYN="N">inflammatory bowel disease</Keyword><Keyword MajorTopicYN="N">ulcerative colitis</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>Competing interests: SL reports non-financial support from Pfizer, non-financial support from Ferring, outside the submitted work. LL has no conflict of interest to declare. NC has no conflict of interest to declare. NAK reports grants from F. Hoffmann-La Roche AG, grants from Biogen, grants from Celltrion Healthcare, grants from Galapagos NV, non-financial support from Immundiagnostik, grants and non-financial support from AbbVie, grants and personal fees from Celltrion, personal fees and non-financial support from Janssen, personal fees from Takeda, personal fees and non-financial support from Dr Falk, outside the submitted work. SCN has served as speakers for Janssen, Abbvie, Takeda, Ferring, Tilotts, Menarini, Pfizer and have received research grants from Olympus, Ferring, Janssen and Abbvie, outside the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>28</Day><Hour>5</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35477864</ArticleId><ArticleId IdType="pmc">PMC9185820</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2021-326784</ArticleId><ArticleId IdType="pii">gutjnl-2021-326784</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhu N, Zhang D, Wang W, et al. . A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727&#x2013;33. 10.1056/NEJMoa2001017</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001017</ArticleId><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu F, Zhao S, Yu B, et al. . A new coronavirus associated with human respiratory disease in China. Nature 2020;579:265&#x2013;9. 10.1038/s41586-020-2008-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2008-3</ArticleId><ArticleId IdType="pmc">PMC7094943</ArticleId><ArticleId IdType="pubmed">32015508</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D, Saunders N, Maes P, et al. . Considerable escape of SARS-CoV-2 omicron to antibody neutralization. Nature 2022;602:671&#x2013;5. 10.1038/s41586-021-04389-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04389-z</ArticleId><ArticleId IdType="pubmed">35016199</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Kr&#xfc;ger N, Schulz S, et al. . The omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell 2022;185:447&#x2013;56. 10.1016/j.cell.2021.12.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.12.032</ArticleId><ArticleId IdType="pmc">PMC8702401</ArticleId><ArticleId IdType="pubmed">35026151</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C, Chen X, Cai Y, et al. . Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;180:934&#x2013;43. 10.1001/jamainternmed.2020.0994</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.0994</ArticleId><ArticleId IdType="pmc">PMC7070509</ArticleId><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng SC, Shi HY, Hamidi N, et al. . Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017;390:2769&#x2013;78. 10.1016/S0140-6736(17)32448-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)32448-0</ArticleId><ArticleId IdType="pubmed">29050646</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuba K, Imai Y, Rao S, et al. . A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005;11:875&#x2013;9. 10.1038/nm1267</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1267</ArticleId><ArticleId IdType="pmc">PMC7095783</ArticleId><ArticleId IdType="pubmed">16007097</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgue&#xf1;o JF, Reich A, Hazime H, et al. . Expression of SARS-CoV-2 entry molecules ACE2 and TMPRSS2 in the gut of patients with IBD. Inflamm Bowel Dis 2020;26:797&#x2013;808. 10.1093/ibd/izaa085</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ibd/izaa085</ArticleId><ArticleId IdType="pmc">PMC7188157</ArticleId><ArticleId IdType="pubmed">32333601</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez-Fari&#xf1;as M, Tokuyama M, Wei G, et al. . Intestinal inflammation modulates the expression of ACE2 and TMPRSS2 and potentially overlaps with the pathogenesis of SARS-CoV-2-related disease. Gastroenterology 2021;160:287&#x2013;301. 10.1053/j.gastro.2020.09.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.09.029</ArticleId><ArticleId IdType="pmc">PMC7516468</ArticleId><ArticleId IdType="pubmed">32980345</ArticleId></ArticleIdList></Reference><Reference><Citation>McAllister MJ, Kirkwood K, Chuah SC, et al. . Intestinal protein characterisation of SARS-CoV-2 entry molecules ACE2 and TMPRSS2 in inflammatory bowel disease (IBD) and fatal COVID-19 infection. Inflammation 2022;45:567&#x2013;72. 10.1007/s10753-021-01567-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-021-01567-z</ArticleId><ArticleId IdType="pmc">PMC8545358</ArticleId><ArticleId IdType="pubmed">34697723</ArticleId></ArticleIdList></Reference><Reference><Citation>Long MD, Martin C, Sandler RS, et al. . Increased risk of pneumonia among patients with inflammatory bowel disease. Am J Gastroenterol 2013;108:240&#x2013;8. 10.1038/ajg.2012.406</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2012.406</ArticleId><ArticleId IdType="pmc">PMC4624299</ArticleId><ArticleId IdType="pubmed">23295276</ArticleId></ArticleIdList></Reference><Reference><Citation>Tinsley A, Navabi S, Williams ED, et al. . Increased risk of influenza and Influenza-Related complications among 140,480 patients with inflammatory bowel disease. Inflamm Bowel Dis 2019;25:369&#x2013;76. 10.1093/ibd/izy243</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ibd/izy243</ArticleId><ArticleId IdType="pubmed">30020478</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirchgesner J, Lemaitre M, Carrat F, et al. . Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology 2018;155:337&#x2013;46. 10.1053/j.gastro.2018.04.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2018.04.012</ArticleId><ArticleId IdType="pubmed">29655835</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonovas S, Fiorino G, Allocca M, et al. . Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol 2016;14:1385&#x2013;97. 10.1016/j.cgh.2016.04.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2016.04.039</ArticleId><ArticleId IdType="pubmed">27189910</ArticleId></ArticleIdList></Reference><Reference><Citation>Melmed GY, Agarwal N, Frenck RW, et al. . Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105:148&#x2013;54. 10.1038/ajg.2009.523</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2009.523</ArticleId><ArticleId IdType="pubmed">19755964</ArticleId></ArticleIdList></Reference><Reference><Citation>deBruyn JCC, Hilsden R, Fonseca K, et al. . Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease. Inflamm Bowel Dis 2012;18:25&#x2013;33. 10.1002/ibd.21706</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ibd.21706</ArticleId><ArticleId IdType="pubmed">21472826</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrisani G, Frasca D, Romero M, et al. . Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-&#x3b1; agents: effects of combined therapy with immunosuppressants. J Crohns Colitis 2013;7:301&#x2013;7. 10.1016/j.crohns.2012.05.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.crohns.2012.05.011</ArticleId><ArticleId IdType="pmc">PMC3862353</ArticleId><ArticleId IdType="pubmed">22673636</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiorino G, Peyrin-Biroulet L, Naccarato P, et al. . Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis 2012;18:1042&#x2013;7. 10.1002/ibd.21800</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ibd.21800</ArticleId><ArticleId IdType="pubmed">21674732</ArticleId></ArticleIdList></Reference><Reference><Citation>Norsa L, Cosimo P, Indriolo A, et al. . Asymptomatic severe acute respiratory syndrome coronavirus 2 infection in patients with inflammatory bowel disease under biologic treatment. Gastroenterology 2020;159:2229&#x2013;31. 10.1053/j.gastro.2020.08.046</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.08.046</ArticleId><ArticleId IdType="pmc">PMC7448738</ArticleId><ArticleId IdType="pubmed">32860790</ArticleId></ArticleIdList></Reference><Reference><Citation>Marafini I, Salvatori S, Sena G, et al. . Low frequency of COVID-19 in inflammatory bowel diseases. Dig Liver Dis 2020;52:1234&#x2013;5. 10.1016/j.dld.2020.06.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2020.06.007</ArticleId><ArticleId IdType="pmc">PMC7293454</ArticleId><ArticleId IdType="pubmed">32601036</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzello F, Calabrese C, Salice M, et al. . COVID-19 in IBD: the experience of a single tertiary IBD center. Dig Liver Dis 2021;53:271&#x2013;6. 10.1016/j.dld.2020.12.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2020.12.012</ArticleId><ArticleId IdType="pmc">PMC7764386</ArticleId><ArticleId IdType="pubmed">33451910</ArticleId></ArticleIdList></Reference><Reference><Citation>Taxonera C, Sagastagoitia I, Alba C, et al. . 2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases. Aliment Pharmacol Ther 2020;52:276&#x2013;83. 10.1111/apt.15804</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15804</ArticleId><ArticleId IdType="pmc">PMC7267496</ArticleId><ArticleId IdType="pubmed">32359205</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan N, Patel D, Xie D, et al. . Are patients with inflammatory bowel disease at an increased risk of developing SARS-CoV-2 than patients without inflammatory bowel disease? results from a nationwide veterans' Affairs cohort study. Am J Gastroenterol 2021;116:808&#x2013;10. 10.14309/ajg.0000000000001012</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000001012</ArticleId><ArticleId IdType="pubmed">33982951</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadi Y, Dulai PS, Kupec J, et al. . Incidence, outcomes, and impact of COVID-19 on inflammatory bowel disease: propensity matched research network analysis. Aliment Pharmacol Ther 2022;55:191&#x2013;200. 10.1111/apt.16730</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.16730</ArticleId><ArticleId IdType="pubmed">34904240</ArticleId></ArticleIdList></Reference><Reference><Citation>Attauabi M, Poulsen A, Theede K, et al. . Prevalence and outcomes of COVID-19 among patients with inflammatory bowel Disease-A Danish prospective population-based cohort study. J Crohns Colitis 2021;15:540&#x2013;50. 10.1093/ecco-jcc/jjaa205</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjaa205</ArticleId><ArticleId IdType="pmc">PMC7797764</ArticleId><ArticleId IdType="pubmed">33035299</ArticleId></ArticleIdList></Reference><Reference><Citation>Mak JWY, Weng M-T, Wei SC, et al. . Zero COVID-19 infection in inflammatory bowel disease patients: findings from population-based inflammatory bowel disease registries in Hong Kong and Taiwan. J Gastroenterol Hepatol 2021;36:171&#x2013;3. 10.1111/jgh.15164</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgh.15164</ArticleId><ArticleId IdType="pmc">PMC7361268</ArticleId><ArticleId IdType="pubmed">32589798</ArticleId></ArticleIdList></Reference><Reference><Citation>Chanchlani N, Lin S, Chee D, et al. . Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11 422 Biologic-Treated patients. J Crohns Colitis 2022;16:389&#x2013;97. 10.1093/ecco-jcc/jjab153</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjab153</ArticleId><ArticleId IdType="pmc">PMC8499950</ArticleId><ArticleId IdType="pubmed">34473254</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy NA, Goodhand JR, Bewshea C, et al. . Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut 2021;70:865&#x2013;75. 10.1136/gutjnl-2021-324388</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324388</ArticleId><ArticleId IdType="pubmed">33753421</ArticleId></ArticleIdList></Reference><Reference><Citation>Sima AR, Saberzadeh-Ardestani B, Vahedi H, et al. . Outcomes of COVID-19 in patients with inflammatory bowel disease: comparison with household members and the role of IBD medications. Arch Iran Med 2022;25:17&#x2013;25. 10.34172/aim.2022.04</Citation><ArticleIdList><ArticleId IdType="doi">10.34172/aim.2022.04</ArticleId><ArticleId IdType="pubmed">35128908</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh AK, Jena A, Kumar-M P, et al. . Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. United European Gastroenterol J 2021;9:159&#x2013;76. 10.1177/2050640620972602</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2050640620972602</ArticleId><ArticleId IdType="pmc">PMC8250629</ArticleId><ArticleId IdType="pubmed">33210980</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubatan J, Levitte S, Balabanis T, et al. . SARS-CoV-2 testing, prevalence, and predictors of COVID-19 in patients with inflammatory bowel disease in northern California. Gastroenterology 2020;159:1141&#x2013;4. 10.1053/j.gastro.2020.05.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.05.009</ArticleId><ArticleId IdType="pmc">PMC7204754</ArticleId><ArticleId IdType="pubmed">32387541</ArticleId></ArticleIdList></Reference><Reference><Citation>Berte' R, Mazza S, Stefanucci MR, et al. . Seroprevalence of SARS-CoV2 in IBD patients treated with biologic therapy. J Crohns Colitis 2021;15:864&#x2013;8. 10.1093/ecco-jcc/jjaa237</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjaa237</ArticleId><ArticleId IdType="pmc">PMC7717179</ArticleId><ArticleId IdType="pubmed">33211810</ArticleId></ArticleIdList></Reference><Reference><Citation>
COVID-19 and IBD reporting database [Internet]. SECURE-IBD Database, 2020. Available: http://covidibd.org [Accessed 10 Feb 2022].</Citation></Reference><Reference><Citation>Brenner EJ, Ungaro RC, Gearry RB, et al. . Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology 2020;159:481&#x2013;91. 10.1053/j.gastro.2020.05.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.05.032</ArticleId><ArticleId IdType="pmc">PMC7233252</ArticleId><ArticleId IdType="pubmed">32425234</ArticleId></ArticleIdList></Reference><Reference><Citation>Ungaro RC, Brenner EJ, Gearry RB, et al. . Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut 2021;70:725&#x2013;32. 10.1136/gutjnl-2020-322539</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-322539</ArticleId><ArticleId IdType="pmc">PMC8136807</ArticleId><ArticleId IdType="pubmed">33082265</ArticleId></ArticleIdList></Reference><Reference><Citation>Ungaro RC, Brenner EJ, Agrawal M, et al. . Impact of medications on COVID-19 outcomes in inflammatory bowel disease: analysis of more than 6000 patients from an international registry. Gastroenterology 2022;162:316&#x2013;9. 10.1053/j.gastro.2021.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2021.09.011</ArticleId><ArticleId IdType="pmc">PMC8437703</ArticleId><ArticleId IdType="pubmed">34529987</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal M, Zhang X, Brenner EJ, et al. . The impact of Vedolizumab on COVID-19 outcomes among adult IBD patients in the SECURE-IBD registry. J Crohns Colitis 2021;15:1877&#x2013;84. 10.1093/ecco-jcc/jjab071</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjab071</ArticleId><ArticleId IdType="pmc">PMC8083188</ArticleId><ArticleId IdType="pubmed">33884425</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal M, Brenner EJ, Zhang X, et al. . Characteristics and outcomes of IBD patients with COVID-19 on tofacitinib therapy in the SECURE-IBD registry. Inflamm Bowel Dis 2021;27:585&#x2013;9. 10.1093/ibd/izaa303</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ibd/izaa303</ArticleId><ArticleId IdType="pmc">PMC7799122</ArticleId><ArticleId IdType="pubmed">33325523</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh AK, Jena A, Kumar-M P, et al. . Clinical presentation of COVID-19 in patients with inflammatory bowel disease: a systematic review and meta-analysis. Intest Res 2022;20:134&#x2013;43. 10.5217/ir.2020.00108</Citation><ArticleIdList><ArticleId IdType="doi">10.5217/ir.2020.00108</ArticleId><ArticleId IdType="pmc">PMC8831773</ArticleId><ArticleId IdType="pubmed">33440918</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Khan A, Chowdhry M, et al. . Risk of severe coronavirus disease 2019 in patients with inflammatory bowel disease in the United States: a multicenter research network study. Gastroenterology 2020;159:1575&#x2013;8. 10.1053/j.gastro.2020.06.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.06.003</ArticleId><ArticleId IdType="pmc">PMC7702184</ArticleId><ArticleId IdType="pubmed">32522507</ArticleId></ArticleIdList></Reference><Reference><Citation>Creemers RH, Rezazadeh Ardabili A, Jonkers DM, et al. . Severe COVID-19 in inflammatory bowel disease patients in a population-based setting. PLoS One 2021;16:e0258271. 10.1371/journal.pone.0258271</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0258271</ArticleId><ArticleId IdType="pmc">PMC8491900</ArticleId><ArticleId IdType="pubmed">34610041</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezzio C, Saibeni S, Variola A, et al. . Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut 2020;69:1213&#x2013;7. 10.1136/gutjnl-2020-321411</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-321411</ArticleId><ArticleId IdType="pubmed">32354990</ArticleId></ArticleIdList></Reference><Reference><Citation>Derikx LAAP, Lantinga MA, de Jong DJ, et al. . Clinical outcomes of Covid-19 in patients with inflammatory bowel disease: a nationwide cohort study. J Crohns Colitis 2021;15:529&#x2013;39. 10.1093/ecco-jcc/jjaa215</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjaa215</ArticleId><ArticleId IdType="pmc">PMC7665430</ArticleId><ArticleId IdType="pubmed">33079178</ArticleId></ArticleIdList></Reference><Reference><Citation>Queiroz NSF, Martins CdeA, Quaresma AB, et al. . COVID-19 outcomes in patients with inflammatory bowel diseases in Latin America: results from SECURE-IBD registry. J Gastroenterol Hepatol 2021;36:3033&#x2013;40. 10.1111/jgh.15588</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgh.15588</ArticleId><ArticleId IdType="pmc">PMC8447321</ArticleId><ArticleId IdType="pubmed">34151470</ArticleId></ArticleIdList></Reference><Reference><Citation>Bamias G, Kokkotis G, Christidou A, et al. . The natural history of COVID-19 in patients with inflammatory bowel disease: a nationwide study by the Hellenic Society for the study of IBD. Eur J Gastroenterol Hepatol 2021;33:e810&#x2013;7. 10.1097/MEG.0000000000002267</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0000000000002267</ArticleId><ArticleId IdType="pmc">PMC8734573</ArticleId><ArticleId IdType="pubmed">34402469</ArticleId></ArticleIdList></Reference><Reference><Citation>
MacKenna B, Kennedy NA, Mehkar A. Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune modifying therapies: a nationwide cohort study in the OpenSAFELY platform [Internet]. bioRxiv
2021. 
http://medrxiv.org/lookup/doi/10.1101/2021.09.03.21262888
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9179144</ArticleId><ArticleId IdType="pubmed">35698725</ArticleId></ArticleIdList></Reference><Reference><Citation>Wetwittayakhlang P, Albader F, Golovics PA, et al. . Clinical outcomes of COVID-19 and impact on disease course in patients with inflammatory bowel disease. Can J Gastroenterol Hepatol 2021;2021:7591141. 10.1155/2021/7591141</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/7591141</ArticleId><ArticleId IdType="pmc">PMC8632463</ArticleId><ArticleId IdType="pubmed">34858891</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal M, Brenner EJ, Yan Mak JW, et al. . COVID-19 outcomes among racial and ethnic minority individuals with inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol 2021;19:2210&#x2013;3. 10.1016/j.cgh.2021.05.060</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2021.05.060</ArticleId><ArticleId IdType="pmc">PMC8169727</ArticleId><ArticleId IdType="pubmed">34089848</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy S, Sheikh SZ, Furey TS. A machine learning approach identifies 5-ASA and ulcerative colitis as being linked with higher COVID-19 mortality in patients with IBD. Sci Rep 2021;11:16522. 10.1038/s41598-021-95919-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95919-2</ArticleId><ArticleId IdType="pmc">PMC8363640</ArticleId><ArticleId IdType="pubmed">34389789</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperger J, Shah KS, Lu M, et al. . Development and validation of multivariable prediction models for adverse COVID-19 outcomes in patients with IBD. BMJ Open 2021;11:e049740. 10.1136/bmjopen-2021-049740</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-049740</ArticleId><ArticleId IdType="pmc">PMC8593277</ArticleId><ArticleId IdType="pubmed">34772750</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricciuto A, Lamb CA, Benchimol EI, et al. . Inflammatory bowel disease clinical activity is associated with COVID-19 severity especially in younger patients. J Crohns Colitis 2021. 10.1093/ecco-jcc/jjab172. [Epub ahead of print: 27 Sep 2021].</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjab172</ArticleId><ArticleId IdType="pmc">PMC8522422</ArticleId><ArticleId IdType="pubmed">34570886</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferra&#xf9; F, Ceccato F, Cannav&#xf2; S, et al. . What we have to know about corticosteroids use during Sars-Cov-2 infection. J Endocrinol Invest 2021;44:693&#x2013;701. 10.1007/s40618-020-01384-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40618-020-01384-5</ArticleId><ArticleId IdType="pmc">PMC7454136</ArticleId><ArticleId IdType="pubmed">32860209</ArticleId></ArticleIdList></Reference><Reference><Citation>Velayos FS, Dusendang JR, Schmittdiel JA. Prior immunosuppressive therapy and severe illness among patients diagnosed with SARS-CoV-2: a community-based study. J Gen Intern Med 2021;36:3794&#x2013;801. 10.1007/s11606-021-07152-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-021-07152-2</ArticleId><ArticleId IdType="pmc">PMC8477718</ArticleId><ArticleId IdType="pubmed">34581984</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan N, Mahmud N, Trivedi C, et al. . Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans affair healthcare system. Gut 2021;70:1657&#x2013;64. 10.1136/gutjnl-2021-324356</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324356</ArticleId><ArticleId IdType="pmc">PMC7985980</ArticleId><ArticleId IdType="pubmed">33753416</ArticleId></ArticleIdList></Reference><Reference><Citation>Ungaro RC, Agrawal M, Park S, et al. . Autoimmune and chronic inflammatory disease patients with COVID-19. ACR Open Rheumatol 2021;3:111&#x2013;5. 10.1002/acr2.11221</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr2.11221</ArticleId><ArticleId IdType="pmc">PMC7882518</ArticleId><ArticleId IdType="pubmed">33527691</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripathi K, Godoy Brewer G, Thu Nguyen M, et al. . COVID-19 and outcomes in patients with inflammatory bowel disease: systematic review and meta-analysis. Inflamm Bowel Dis 2021. 10.1093/ibd/izab236. [Epub ahead of print: 27 Oct 2021].</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ibd/izab236</ArticleId><ArticleId IdType="pmc">PMC8574492</ArticleId><ArticleId IdType="pubmed">34718595</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke KE, Kochar B, Allegretti JR, et al. . Immunosuppressive therapy and risk of COVID-19 infection in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2021;27:155&#x2013;61. 10.1093/ibd/izaa278</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ibd/izaa278</ArticleId><ArticleId IdType="pmc">PMC7665507</ArticleId><ArticleId IdType="pubmed">33089863</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer A, Semenzato L, Zureik M, et al. . Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study. Aliment Pharmacol Ther 2021;54:160&#x2013;6. 10.1111/apt.16410</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.16410</ArticleId><ArticleId IdType="pubmed">34110040</ArticleId></ArticleIdList></Reference><Reference><Citation>Ardizzone S, Ferretti F, Monico MC, et al. . Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapy. J Gastroenterol Hepatol 2021;36:3050&#x2013;5. 10.1111/jgh.15591</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgh.15591</ArticleId><ArticleId IdType="pmc">PMC8447454</ArticleId><ArticleId IdType="pubmed">34159648</ArticleId></ArticleIdList></Reference><Reference><Citation>Izadi Z, Brenner EJ, Mahil SK, et al. . Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19. JAMA Netw Open 2021;4:e2129639. 10.1001/jamanetworkopen.2021.29639</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.29639</ArticleId><ArticleId IdType="pmc">PMC8524310</ArticleId><ArticleId IdType="pubmed">34661663</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandborn WJ, Feagan BG, Rutgeerts P, et al. . Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711&#x2013;21. 10.1056/NEJMoa1215739</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1215739</ArticleId><ArticleId IdType="pubmed">23964933</ArticleId></ArticleIdList></Reference><Reference><Citation>Feagan BG, Bhayat F, Khalid M, et al. . Respiratory tract infections in patients with inflammatory bowel disease: safety analyses from Vedolizumab clinical trials. J Crohns Colitis 2018;12:905&#x2013;19. 10.1093/ecco-jcc/jjy047</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjy047</ArticleId><ArticleId IdType="pmc">PMC6065483</ArticleId><ArticleId IdType="pubmed">29788248</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandborn WJ, Su C, Sands BE, et al. . Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017;376:1723&#x2013;36. 10.1056/NEJMoa1606910</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1606910</ArticleId><ArticleId IdType="pubmed">28467869</ArticleId></ArticleIdList></Reference><Reference><Citation>Guimar&#xe3;es PO, Quirk D, Furtado RH, et al. . Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med 2021;385:406&#x2013;15. 10.1056/NEJMoa2101643</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101643</ArticleId><ArticleId IdType="pmc">PMC8220898</ArticleId><ArticleId IdType="pubmed">34133856</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukin DJ, Funez-dePagnier G, Lima S, et al. . No durable impact of COVID-19 on intestinal disease activity in subjects with IBD. Clin Gastroenterol Hepatol 2021;19:2312&#x2013;4. 10.1016/j.cgh.2021.06.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2021.06.008</ArticleId><ArticleId IdType="pmc">PMC8178538</ArticleId><ArticleId IdType="pubmed">34102340</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurath MF. COVID-19 and immunomodulation in IBD. Gut 2020;69:1335&#x2013;42. 10.1136/gutjnl-2020-321269</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-321269</ArticleId><ArticleId IdType="pmc">PMC7211083</ArticleId><ArticleId IdType="pubmed">32303609</ArticleId></ArticleIdList></Reference><Reference><Citation>Mylonaki M, Langmead L, Pantes A, et al. . Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol 2004;16:775&#x2013;8. 10.1097/01.meg.0000131040.38607.09</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.meg.0000131040.38607.09</ArticleId><ArticleId IdType="pubmed">15256979</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, et al. . A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 2022;22:e102&#x2013;7. 10.1016/S1473-3099(21)00703-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H, Raza S, Nowell J, et al. . Long covid-mechanisms, risk factors, and management. BMJ 2021;374:n1648. 10.1136/bmj.n1648</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F, et al. . Persistent symptoms in patients after acute COVID-19. JAMA 2020;324:603&#x2013;5. 10.1001/jama.2020.12603</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Chopra V, Flanders SA, O'Malley M, et al. . Sixty-Day outcomes among patients hospitalized with COVID-19. Ann Intern Med 2021;174:576&#x2013;8. 10.7326/M20-5661</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-5661</ArticleId><ArticleId IdType="pmc">PMC7707210</ArticleId><ArticleId IdType="pubmed">33175566</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, et al. . 6-Month consequences of COVID-19 in patients discharged from Hospital: a cohort study. Lancet 2021;397:220&#x2013;32. 10.1016/S0140-6736(20)32656-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin M, Schommers P, Stecher M, et al. . Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health Eur 2021;6:100122. 10.1016/j.lanepe.2021.100122</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100122</ArticleId><ArticleId IdType="pmc">PMC8129613</ArticleId><ArticleId IdType="pubmed">34027514</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvatori S, Baldassarre F, Mossa M, et al. . Long COVID in inflammatory bowel diseases. J Clin Med 2021;10:5575. 10.3390/jcm10235575</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10235575</ArticleId><ArticleId IdType="pmc">PMC8658587</ArticleId><ArticleId IdType="pubmed">34884276</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Mak JWY, Su Q, et al. . Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut 2022;71:544&#x2013;52. 10.1136/gutjnl-2021-325989</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-325989</ArticleId><ArticleId IdType="pubmed">35082169</ArticleId></ArticleIdList></Reference><Reference><Citation>Magro F, Rahier J-F, Abreu C, et al. . Inflammatory bowel disease management during the COVID-19 outbreak: the ten do's and don'ts from the ECCO-COVID Taskforce. J Crohns Colitis 2020;14:S798&#x2013;806. 10.1093/ecco-jcc/jjaa160</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjaa160</ArticleId><ArticleId IdType="pmc">PMC7454472</ArticleId><ArticleId IdType="pubmed">32722754</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin DT, Feuerstein JD, Wang AY, et al. . AGA clinical practice update on management of inflammatory bowel disease during the COVID-19 pandemic: expert commentary. Gastroenterology 2020;159:350&#x2013;7. 10.1053/j.gastro.2020.04.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.04.012</ArticleId><ArticleId IdType="pmc">PMC7151253</ArticleId><ArticleId IdType="pubmed">32283100</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy NA, Jones G-R, Lamb CA, et al. . British Society of gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut 2020;69:984&#x2013;90. 10.1136/gutjnl-2020-321244</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-321244</ArticleId><ArticleId IdType="pmc">PMC7211081</ArticleId><ArticleId IdType="pubmed">32303607</ArticleId></ArticleIdList></Reference><Reference><Citation>Targownik LE, Bernstein CN, Lakatos PL, et al. . Crohn's and colitis Canada's 2021 impact of COVID-19 and inflammatory bowel disease in Canada: risk factors and medications. J Can Assoc Gastroenterol 2021;4:S40&#x2013;5. 10.1093/jcag/gwab032</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jcag/gwab032</ArticleId><ArticleId IdType="pmc">PMC8570417</ArticleId><ArticleId IdType="pubmed">34755038</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakase H, Matsumoto T, Matsuura M, et al. . Expert opinions on the current therapeutic management of inflammatory bowel disease during the COVID-19 pandemic: Japan IBD COVID-19 Taskforce, intractable diseases, the health and labor sciences research. Digestion 2021;102:814&#x2013;22. 10.1159/000510502</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000510502</ArticleId><ArticleId IdType="pmc">PMC7573907</ArticleId><ArticleId IdType="pubmed">32892197</ArticleId></ArticleIdList></Reference><Reference><Citation>Aysha A-A, Rentsch C, Prentice R, et al. . Practical management of inflammatory bowel disease patients during the COVID-19 pandemic: expert commentary from the gastroenterological Society of Australia inflammatory bowel disease faculty. Intern Med J 2020;50:798&#x2013;804. 10.1111/imj.14889</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imj.14889</ArticleId><ArticleId IdType="pmc">PMC7405147</ArticleId><ArticleId IdType="pubmed">32656985</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein CN, Ng SC, Banerjee R, et al. . Worldwide management of inflammatory bowel disease during the COVID-19 pandemic: an international survey. Inflamm Bowel Dis 2021;27:836&#x2013;47. 10.1093/ibd/izaa202</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ibd/izaa202</ArticleId><ArticleId IdType="pmc">PMC7454666</ArticleId><ArticleId IdType="pubmed">32793973</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertani L, Barberio B, Tric&#xf2; D, et al. . Hospitalisation for drug infusion did not increase levels of anxiety and the risk of disease relapse in patients with inflammatory bowel disease during COVID-19 outbreak. J Clin Med 2021;10:3270. 10.3390/jcm10153270</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10153270</ArticleId><ArticleId IdType="pmc">PMC8348517</ArticleId><ArticleId IdType="pubmed">34362053</ArticleId></ArticleIdList></Reference><Reference><Citation>Richez C, Flipo R-M, Berenbaum F, et al. . Managing patients with rheumatic diseases during the COVID-19 pandemic: the French Society of rheumatology answers to most frequently asked questions up to may 2020. Joint Bone Spine 2020;87:431&#x2013;7. 10.1016/j.jbspin.2020.05.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbspin.2020.05.006</ArticleId><ArticleId IdType="pmc">PMC7255274</ArticleId><ArticleId IdType="pubmed">32473418</ArticleId></ArticleIdList></Reference><Reference><Citation>Akintayo RO, Bahiri R, El Miedany Y, et al. . African League against rheumatism (AFLAR) preliminary recommendations on the management of rheumatic diseases during the COVID-19 pandemic. Clin Rheumatol 2021;40:3445&#x2013;54. 10.1007/s10067-020-05355-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-020-05355-2</ArticleId><ArticleId IdType="pmc">PMC7465880</ArticleId><ArticleId IdType="pubmed">32876786</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Assche G, Vermeire S, Ballet V, et al. . Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised switch trial. Gut 2012;61:229&#x2013;34. 10.1136/gutjnl-2011-300755</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2011-300755</ArticleId><ArticleId IdType="pubmed">21948942</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanova MJ, Chaparro M, M&#xed;nguez M, et al. . Effectiveness and safety of the sequential use of a second and third anti-TNF agent in patients with inflammatory bowel disease: results from the Eneida registry. Inflamm Bowel Dis 2020;26:606&#x2013;16. 10.1093/ibd/izz192</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ibd/izz192</ArticleId><ArticleId IdType="pubmed">31504569</ArticleId></ArticleIdList></Reference><Reference><Citation>Roblin X, Williet N, Boschetti G, et al. . Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF Trough levels and antidrug antibodies: a prospective randomised trial. Gut 2020;69:1206&#x2013;12. 10.1136/gutjnl-2019-319758</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2019-319758</ArticleId><ArticleId IdType="pubmed">31980448</ArticleId></ArticleIdList></Reference><Reference><Citation>Arg&#xfc;elles-Arias F, Fern&#xe1;ndez &#xc1;lvarez P, Castro Laria L, et al. . Switch to infliximab subcutaneous during SARS-CoV-2 pandemic: preliminary results. Rev Esp Enferm Dig 2021. 10.17235/reed.2021.8320/2021</Citation><ArticleIdList><ArticleId IdType="doi">10.17235/reed.2021.8320/2021</ArticleId><ArticleId IdType="pubmed">34517718</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma AM, Patel A, Subramanian S, et al. . From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative. Lancet Gastroenterol Hepatol 2021;6:88&#x2013;9. 10.1016/S2468-1253(20)30392-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30392-7</ArticleId><ArticleId IdType="pubmed">33444534</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen R, Meade S, Beattie RM, et al. . Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a Rand appropriateness panel. Gut 2021;70:1044&#x2013;52. 10.1136/gutjnl-2020-322449</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-322449</ArticleId><ArticleId IdType="pubmed">32873696</ArticleId></ArticleIdList></Reference><Reference><Citation>Din S, Kent A, Pollok RC, et al. . Adaptations to the British Society of gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a Rand appropriateness panel. Gut 2020;69:1769&#x2013;77. 10.1136/gutjnl-2020-321927</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-321927</ArticleId><ArticleId IdType="pmc">PMC7299646</ArticleId><ArticleId IdType="pubmed">32513653</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebastian S, Walker GJ, Kennedy NA, et al. . Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. Lancet Gastroenterol Hepatol 2021;6:271&#x2013;81. 10.1016/S2468-1253(21)00016-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(21)00016-9</ArticleId><ArticleId IdType="pmc">PMC7906670</ArticleId><ArticleId IdType="pubmed">33545083</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebastian S, Patel KV, Segal JP, et al. . Ambulatory care management of 69 patients with acute severe ulcerative colitis in comparison to 695 inpatients: insights from a multicentre UK cohort study. BMJ Open Gastroenterol 2022;9:e000763. 10.1136/bmjgast-2021-000763</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgast-2021-000763</ArticleId><ArticleId IdType="pmc">PMC8804638</ArticleId><ArticleId IdType="pubmed">35101886</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X-R, Zhang Y-F, Lan N, et al. . Practice patterns of colorectal surgery during the COVID-19 pandemic. Dis Colon Rectum 2020;63:1572&#x2013;4. 10.1097/DCR.0000000000001840</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/DCR.0000000000001840</ArticleId><ArticleId IdType="pmc">PMC7641176</ArticleId><ArticleId IdType="pubmed">33149016</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel CA, Christensen B, Kornbluth A, et al. . Guidance for restarting inflammatory bowel disease therapy in patients who Withheld immunosuppressant medications during COVID-19. J Crohns Colitis 2020;14:S769&#x2013;73. 10.1093/ecco-jcc/jjaa135</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjaa135</ArticleId><ArticleId IdType="pmc">PMC7665410</ArticleId><ArticleId IdType="pubmed">33085972</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group, Horby P, Lim WS, et al. . Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021;384:693&#x2013;704. 10.1056/NEJMoa2021436</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner D, Huang Y, Mart&#xed;n-de-Carpi J, et al. . Corona virus disease 2019 and paediatric inflammatory bowel diseases: global experience and provisional guidance (March 2020) from the paediatric IBD Porto group of European Society of paediatric gastroenterology, hepatology, and nutrition. J Pediatr Gastroenterol Nutr 2020;70:727&#x2013;33. 10.1097/MPG.0000000000002729</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000002729</ArticleId><ArticleId IdType="pmc">PMC7273950</ArticleId><ArticleId IdType="pubmed">32443020</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner EJ, Pigneur B, Focht G, et al. . Benign evolution of SARS-Cov2 infections in children with inflammatory bowel disease: results from two international databases. Clin Gastroenterol Hepatol 2021;19:394&#x2013;6. 10.1016/j.cgh.2020.10.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2020.10.010</ArticleId><ArticleId IdType="pmc">PMC7550063</ArticleId><ArticleId IdType="pubmed">33059040</ArticleId></ArticleIdList></Reference><Reference><Citation>Benchimol EI, Carroll MW, Geist R, et al. . Crohn's and colitis Canada's 2021 impact of COVID-19 and inflammatory bowel disease in Canada: children and expectant mothers with inflammatory bowel disease. J Can Assoc Gastroenterol 2021;4:S27&#x2013;33. 10.1093/jcag/gwab030</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jcag/gwab030</ArticleId><ArticleId IdType="pmc">PMC8570420</ArticleId><ArticleId IdType="pubmed">34755036</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan W, Ihekweazu F, Walsh S, et al. . SARS-COV-2 infection and seroconversion in pediatric inflammatory bowel disease patients. Inflamm Bowel Dis 2021;27:S44&#x2013;5. 10.1093/ibd/izaa347.108</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ibd/izaa347.108</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrigo S, Alvisi P, Banzato C, et al. . Management of paediatric IBD after the peak of COVID-19 pandemic in Italy: a position paper on behalf of the SIGENP IBD Working group. Dig Liver Dis 2021;53:183&#x2013;9. 10.1016/j.dld.2020.10.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2020.10.024</ArticleId><ArticleId IdType="pmc">PMC7580561</ArticleId><ArticleId IdType="pubmed">33132063</ArticleId></ArticleIdList></Reference><Reference><Citation>Korean Society of Infectious Diseases, Korean Society of Pediatric Infectious Diseases, Korean Society of Epidemiology, et al. . Report on the epidemiological features of coronavirus disease 2019 (COVID-19) outbreak in the Republic of Korea from January 19 to March 2, 2020. J Korean Med Sci 2020;35:e112. 10.3346/jkms.2020.35.e112</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2020.35.e112</ArticleId><ArticleId IdType="pmc">PMC7073313</ArticleId><ArticleId IdType="pubmed">32174069</ArticleId></ArticleIdList></Reference><Reference><Citation>Riphagen S, Gomez X, Gonzalez-Martinez C, et al. . Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 2020;395:1607&#x2013;8. 10.1016/S0140-6736(20)31094-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31094-1</ArticleId><ArticleId IdType="pmc">PMC7204765</ArticleId><ArticleId IdType="pubmed">32386565</ArticleId></ArticleIdList></Reference><Reference><Citation>Meredith J, Khedim C-A, Henderson P, et al. . Paediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 [PIMS-TS] in a Patient Receiving Infliximab Therapy for Inflammatory Bowel Disease. J Crohns Colitis 2021;15:687&#x2013;91. 10.1093/ecco-jcc/jjaa201</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjaa201</ArticleId><ArticleId IdType="pmc">PMC7543345</ArticleId><ArticleId IdType="pubmed">32997749</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolinger MT, Person H, Smith R, et al. . Pediatric Crohn disease and multisystem inflammatory syndrome in children (MIS-C) and COVID-19 treated with infliximab. J Pediatr Gastroenterol Nutr 2020;71:153&#x2013;5. 10.1097/MPG.0000000000002809</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000002809</ArticleId><ArticleId IdType="pmc">PMC7268863</ArticleId><ArticleId IdType="pubmed">32452979</ArticleId></ArticleIdList></Reference><Reference><Citation>De Lima-Karagiannis A, Juillerat P, Sebastian S, et al. . Management of pregnant inflammatory bowel disease patients during the COVID-19 pandemic. J Crohns Colitis 2020;14:S807&#x2013;14. 10.1093/ecco-jcc/jjaa125</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjaa125</ArticleId><ArticleId IdType="pmc">PMC7665400</ArticleId><ArticleId IdType="pubmed">33085970</ArticleId></ArticleIdList></Reference><Reference><Citation>Selinger CP, Fraser A, Collins P, et al. . Impact of the coronavirus infectious disease (COVID-19) pandemic on the provision of inflammatory bowel disease (IBD) antenatal care and outcomes of pregnancies in women with IBD. BMJ Open Gastroenterol 2021;8:e000603. 10.1136/bmjgast-2021-000603</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgast-2021-000603</ArticleId><ArticleId IdType="pmc">PMC7985978</ArticleId><ArticleId IdType="pubmed">33753426</ArticleId></ArticleIdList></Reference><Reference><Citation>Prentice RE, Ross AL, Flanagan EK. Management of pregnant women with inflammatory bowel disease and COVID-19-Balancing risks of delayed treatment Recommencement. J Crohns Colitis 2021:jjab214. 10.1093/ecco-jcc/jjab214</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjab214</ArticleId><ArticleId IdType="pubmed">34888653</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen MH, Axelrad J, Hudesman D, et al. . Management of acute severe ulcerative colitis in a pregnant woman with COVID-19 infection: a case report and review of the literature. Inflamm Bowel Dis 2020;26:971&#x2013;3. 10.1093/ibd/izaa109</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ibd/izaa109</ArticleId><ArticleId IdType="pmc">PMC7239163</ArticleId><ArticleId IdType="pubmed">32393973</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui RN, Wong SH, S&#xe1;nchez-Luna SA, et al. . Overview of guidance for endoscopy during the coronavirus disease 2019 pandemic. J Gastroenterol Hepatol 2020;35:749&#x2013;59. 10.1111/jgh.15053</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgh.15053</ArticleId><ArticleId IdType="pubmed">32233034</ArticleId></ArticleIdList></Reference><Reference><Citation>Kushnir VM, Berzin TM, Elmunzer BJ, et al. . Plans to reactivate gastroenterology practices following the COVID-19 pandemic: a survey of North American centers. Clin Gastroenterol Hepatol 2020;18:2287&#x2013;94. 10.1016/j.cgh.2020.05.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2020.05.030</ArticleId><ArticleId IdType="pmc">PMC7242181</ArticleId><ArticleId IdType="pubmed">32447019</ArticleId></ArticleIdList></Reference><Reference><Citation>Repici A, Pace F, Gabbiadini R, et al. . Endoscopy Units and the Coronavirus Disease 2019 Outbreak: A Multicenter Experience From Italy. Gastroenterology 2020;159:363&#x2013;6. 10.1053/j.gastro.2020.04.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.04.003</ArticleId><ArticleId IdType="pmc">PMC7151374</ArticleId><ArticleId IdType="pubmed">32283102</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennessy B, Vicari J, Bernstein B, et al. . Guidance for resuming Gi endoscopy and practice operations after the COVID-19 pandemic. Gastrointest Endosc 2020;92:743&#x2013;7. 10.1016/j.gie.2020.05.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gie.2020.05.006</ArticleId><ArticleId IdType="pmc">PMC7211716</ArticleId><ArticleId IdType="pubmed">32437712</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu PWY, Ng SC, Inoue H, et al. . Practice of endoscopy during COVID-19 pandemic: position statements of the Asian Pacific Society for digestive endoscopy (APSDE-COVID statements). Gut 2020;69:991&#x2013;6. 10.1136/gutjnl-2020-321185</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-321185</ArticleId><ArticleId IdType="pmc">PMC7211066</ArticleId><ArticleId IdType="pubmed">32241897</ArticleId></ArticleIdList></Reference><Reference><Citation>Furfaro F, Vuitton L, Fiorino G, et al. . SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience. Nat Rev Gastroenterol Hepatol 2020;17:507&#x2013;16. 10.1038/s41575-020-0319-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-020-0319-3</ArticleId><ArticleId IdType="pmc">PMC7288265</ArticleId><ArticleId IdType="pubmed">32528139</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai N, Mei Z, Zhang W, et al. . Endoscopy works during the pandemic of coronavirus COVID-19: recommendations by the Chinese Society of digestive endoscopy. United European Gastroenterol J 2020;8:798&#x2013;803. 10.1177/2050640620930632</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2050640620930632</ArticleId><ArticleId IdType="pmc">PMC7335943</ArticleId><ArticleId IdType="pubmed">32615871</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro Filho EC, Castro R, Fernandes FF, et al. . Gastrointestinal endoscopy during the COVID-19 pandemic: an updated review of guidelines and statements from international and national societies. Gastrointest Endosc 2020;92:440&#x2013;5. 10.1016/j.gie.2020.03.3854</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gie.2020.03.3854</ArticleId><ArticleId IdType="pmc">PMC7130800</ArticleId><ArticleId IdType="pubmed">32268135</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng SC, Mak JWY, Hitz L, et al. . COVID-19 pandemic: which IBD patients need to be Scoped-Who gets Scoped now, who can wait, and how to resume to normal. J Crohns Colitis 2020;14:S791&#x2013;7. 10.1093/ecco-jcc/jjaa128</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjaa128</ArticleId><ArticleId IdType="pmc">PMC7665406</ArticleId><ArticleId IdType="pubmed">33085973</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacucci M, Cannatelli R, Labarile N, et al. . Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period. Lancet Gastroenterol Hepatol 2020;5:598&#x2013;606. 10.1016/S2468-1253(20)30119-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30119-9</ArticleId><ArticleId IdType="pmc">PMC7162648</ArticleId><ArticleId IdType="pubmed">32305075</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutter MD, Brookes M, Lee TJ, et al. . Impact of the COVID-19 pandemic on UK endoscopic activity and cancer detection: a national endoscopy database analysis. Gut 2021;70:537&#x2013;43. 10.1136/gutjnl-2020-322179</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-322179</ArticleId><ArticleId IdType="pubmed">32690602</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman HW, Chen Z, Niles J, et al. . Changes in the number of US patients with newly identified cancer before and during the coronavirus disease 2019 (COVID-19) pandemic. JAMA Netw Open 2020;3:e2017267. 10.1001/jamanetworkopen.2020.17267</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.17267</ArticleId><ArticleId IdType="pmc">PMC7403918</ArticleId><ArticleId IdType="pubmed">32749465</ArticleId></ArticleIdList></Reference><Reference><Citation>Deputy M, Sahnan K, Worley G, et al. . The use of, and outcomes for, inflammatory bowel disease services during the Covid-19 pandemic: a nationwide observational study. Aliment Pharmacol Ther . 2022;55:836-846. 10.1111/apt.16800</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.16800</ArticleId><ArticleId IdType="pmc">PMC9111430</ArticleId><ArticleId IdType="pubmed">35132663</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau LHS, Wong SH, Yip TCF, et al. . Collateral effect of coronavirus disease 2019 pandemic on hospitalizations and clinical outcomes in gastrointestinal and liver diseases: a Territory-wide observational study in Hong Kong. Gastroenterology 2020;159:1979&#x2013;81. 10.1053/j.gastro.2020.07.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.07.042</ArticleId><ArticleId IdType="pmc">PMC7382332</ArticleId><ArticleId IdType="pubmed">32721440</ArticleId></ArticleIdList></Reference><Reference><Citation>Magro F, Nuzzo A, Abreu C, et al. . COVID-19 in gastroenterology: where are we now? Current evidence on the impact of COVID-19 in gastroenterology. United European Gastroenterol J 2021;9:750&#x2013;65. 10.1002/ueg2.12115</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ueg2.12115</ArticleId><ArticleId IdType="pmc">PMC8435247</ArticleId><ArticleId IdType="pubmed">34190413</ArticleId></ArticleIdList></Reference><Reference><Citation>Din S, Gaya D, Kammermeier J, et al. . Inflammatory bowel disease clinical service recovery during the COVID-19 pandemic. Frontline Gastroenterol 2022;13:77&#x2013;81. 10.1136/flgastro-2021-101805</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/flgastro-2021-101805</ArticleId><ArticleId IdType="pmc">PMC8666864</ArticleId><ArticleId IdType="pubmed">34966535</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho KMA, Banerjee A, Lawler M, et al. . Predicting endoscopic activity recovery in England after COVID-19: a national analysis. Lancet Gastroenterol Hepatol 2021;6:381&#x2013;90. 10.1016/S2468-1253(21)00058-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(21)00058-3</ArticleId><ArticleId IdType="pmc">PMC7946568</ArticleId><ArticleId IdType="pubmed">33713606</ArticleId></ArticleIdList></Reference><Reference><Citation>Din S, Gaya DR, Arnott IDR. COVID-19: colorectal cancer endoscopic surveillance in IBD. Lancet Gastroenterol Hepatol 2021;6:526&#x2013;7. 10.1016/S2468-1253(21)00168-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(21)00168-0</ArticleId><ArticleId IdType="pmc">PMC8192092</ArticleId><ArticleId IdType="pubmed">34119037</ArticleId></ArticleIdList></Reference><Reference><Citation>
British Society of Gastroenterology . An update to information and guidance for endoscopy services in the COVID-19 pandemic, 2021. Available: https://www.bsg.org.uk/covid-19-advice/an-update-to-information-and-guidance-for-endoscopy-services-in-the-covid-19-pandemic-2/https://www.bsg.org.uk/covid-19-advice/an-update-to-information-and-guidance-for-endoscopy-services-in-the-covid-19-pandemic-2/ [Accessed 26 Feb 2022].</Citation></Reference><Reference><Citation>Kennedy NA, Hansen R, Younge L, et al. . Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic. Frontline Gastroenterol 2020;11:343&#x2013;50. 10.1136/flgastro-2020-101520</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/flgastro-2020-101520</ArticleId><ArticleId IdType="pmc">PMC7335699</ArticleId><ArticleId IdType="pubmed">32874484</ArticleId></ArticleIdList></Reference><Reference><Citation>Chee D, Nice R, Hamilton B, et al. . Patient-led remote intracapillary pharmacoKinetic sampling (fingerPRICKS) for therapeutic drug monitoring in patients with inflammatory bowel disease. J Crohns Colitis 2022;16:190&#x2013;8. 10.1093/ecco-jcc/jjab128</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjab128</ArticleId><ArticleId IdType="pubmed">34289028</ArticleId></ArticleIdList></Reference><Reference><Citation>Bossuyt P, Pouillon L, Claeys S, et al. . Ultra-proactive therapeutic drug monitoring of infliximab based on point of care testing in inflammatory bowel disease: results of a pragmatic trial. J Crohns Colitis 2022;16:199&#x2013;206. 10.1093/ecco-jcc/jjab127</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjab127</ArticleId><ArticleId IdType="pubmed">34297099</ArticleId></ArticleIdList></Reference><Reference><Citation>Strik AS, L&#xf6;wenberg M, Mould DR, et al. . Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial. Scand J Gastroenterol 2021;56:145&#x2013;54. 10.1080/00365521.2020.1856405</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365521.2020.1856405</ArticleId><ArticleId IdType="pubmed">33290108</ArticleId></ArticleIdList></Reference><Reference><Citation>Shields S, Dunlop A, Seenan JP, et al. . Disease monitoring of biologic treatment in IBD: early impact and future implications of COVID-19 pandemic. Frontline Gastroenterol 2021;12:345&#x2013;7. 10.1136/flgastro-2020-101563</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/flgastro-2020-101563</ArticleId><ArticleId IdType="pmc">PMC8231430</ArticleId><ArticleId IdType="pubmed">34249322</ArticleId></ArticleIdList></Reference><Reference><Citation>Botwin GJ, Li D, Figueiredo J, et al. . Adverse events after SARS-CoV-2 mRNA vaccination among patients with inflammatory bowel disease. Am J Gastroenterol 2021;116:1746&#x2013;51. 10.14309/ajg.0000000000001342</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000001342</ArticleId><ArticleId IdType="pmc">PMC8484025</ArticleId><ArticleId IdType="pubmed">34047304</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver KN, Zhang X, Dai X, et al. . Impact of SARS-CoV-2 vaccination on inflammatory bowel disease activity and development of vaccine-related adverse events: results from PREVENT-COVID. Inflamm Bowel Dis 2021:izab302. 10.1093/ibd/izab302</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ibd/izab302</ArticleId><ArticleId IdType="pmc">PMC8822409</ArticleId><ArticleId IdType="pubmed">34871388</ArticleId></ArticleIdList></Reference><Reference><Citation>Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, et al. . Lower serologic response to COVID-19 mRNA vaccine in patients with inflammatory bowel diseases treated with Anti-TNF&#x3b1;. Gastroenterology 2022;162:454&#x2013;67. 10.1053/j.gastro.2021.10.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2021.10.029</ArticleId><ArticleId IdType="pmc">PMC8552587</ArticleId><ArticleId IdType="pubmed">34717923</ArticleId></ArticleIdList></Reference><Reference><Citation>Caldera F, Hillman L, Saha S, et al. . Immunogenicity of high dose influenza vaccine for patients with inflammatory bowel disease on anti-TNF monotherapy: a randomized clinical trial. Inflamm Bowel Dis 2020;26:593&#x2013;602. 10.1093/ibd/izz164</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ibd/izz164</ArticleId><ArticleId IdType="pubmed">31504526</ArticleId></ArticleIdList></Reference><Reference><Citation>Doornekamp L, Goetgebuer RL, Schmitz KS, et al. . High Immunogenicity to Influenza Vaccination in Crohn&#x2019;s Disease Patients Treated with Ustekinumab. Vaccines 2020;8:455. 10.3390/vaccines8030455</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8030455</ArticleId><ArticleId IdType="pmc">PMC7565576</ArticleId><ArticleId IdType="pubmed">32824111</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng S, Phillips DJ, White T, et al. . Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med 2021;27:2032&#x2013;40. 10.1038/s41591-021-01540-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01540-1</ArticleId><ArticleId IdType="pmc">PMC8604724</ArticleId><ArticleId IdType="pubmed">34588689</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury DS, Cromer D, Reynaldi A, et al. . Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27:1205&#x2013;11. 10.1038/s41591-021-01377-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01377-8</ArticleId><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Premkumar L, Segovia-Chumbez B, Jadi R, et al. . The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol 2020;5:eabc8413. 10.1126/sciimmunol.abc8413</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abc8413</ArticleId><ArticleId IdType="pmc">PMC7292505</ArticleId><ArticleId IdType="pubmed">32527802</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong S-Y, Dixon R, Martinez Pazos V, et al. . Serologic response to messenger RNA coronavirus disease 2019 vaccines in inflammatory bowel disease patients receiving biologic therapies. Gastroenterology 2021;161:715&#x2013;8. 10.1053/j.gastro.2021.04.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2021.04.025</ArticleId><ArticleId IdType="pmc">PMC8055494</ArticleId><ArticleId IdType="pubmed">33887219</ArticleId></ArticleIdList></Reference><Reference><Citation>Kappelman MD, Weaver KN, Boccieri M, et al. . Humoral immune response to messenger RNA COVID-19 vaccines among patients with inflammatory bowel disease. Gastroenterology 2021;161:1340&#x2013;3. 10.1053/j.gastro.2021.06.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2021.06.016</ArticleId><ArticleId IdType="pmc">PMC8321883</ArticleId><ArticleId IdType="pubmed">34144046</ArticleId></ArticleIdList></Reference><Reference><Citation>Melmed GY, Botwin GJ, Sobhani K, et al. . Antibody responses after SARS-CoV-2 mRNA vaccination in adults with inflammatory bowel disease. Ann Intern Med 2021;174:1768&#x2013;70. 10.7326/M21-2483</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-2483</ArticleId><ArticleId IdType="pmc">PMC8513793</ArticleId><ArticleId IdType="pubmed">34633830</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin S, Kennedy NA, Saifuddin A, et al. . Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nat Commun 2022;13:1379. 10.1038/s41467-022-28517-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-28517-z</ArticleId><ArticleId IdType="pmc">PMC8927425</ArticleId><ArticleId IdType="pubmed">35296643</ArticleId></ArticleIdList></Reference><Reference><Citation>Jena A, James D, Singh AK, et al. . Effectiveness and durability of COVID-19 vaccination in 9447 patients with IBD: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2022. 10.1016/j.cgh.2022.02.030. [Epub ahead of print: 19 Feb 2022].</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2022.02.030</ArticleId><ArticleId IdType="pmc">PMC8856753</ArticleId><ArticleId IdType="pubmed">35189387</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. . Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 2020;183:158&#x2013;68. 10.1016/j.cell.2020.08.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.017</ArticleId><ArticleId IdType="pmc">PMC7427556</ArticleId><ArticleId IdType="pubmed">32979941</ArticleId></ArticleIdList></Reference><Reference><Citation>Rydyznski Moderbacher C, Ramirez SI, Dan JM, et al. . Antigen-Specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 2020;183:996&#x2013;1012. 10.1016/j.cell.2020.09.038</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.038</ArticleId><ArticleId IdType="pmc">PMC7494270</ArticleId><ArticleId IdType="pubmed">33010815</ArticleId></ArticleIdList></Reference><Reference><Citation>Bange EM, Han NA, Wileyto P, et al. . CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med 2021;27:1280&#x2013;9. 10.1038/s41591-021-01386-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01386-7</ArticleId><ArticleId IdType="pmc">PMC8291091</ArticleId><ArticleId IdType="pubmed">34017137</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds CJ, Swadling L, Gibbons JM, et al. . Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. Sci Immunol 2020;5:eabf3698. 10.1126/sciimmunol.abf3698</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abf3698</ArticleId><ArticleId IdType="pmc">PMC8101131</ArticleId><ArticleId IdType="pubmed">33361161</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D, Xu A, Mengesha E, et al. . The T-cell clonal response to SARS-CoV-2 vaccination in inflammatory bowel disease patients is augmented by anti-TNF therapy and often deficient in antibody-responders. medRxiv 2021. 10.1101/2021.12.08.21267444. [Epub ahead of print: 08 Dec 2021].</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.08.21267444</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerna K, Duricova D, Lukas M, et al. . Anti-SARS-CoV-2 vaccination and antibody response in patients with inflammatory bowel disease on Immune-modifying therapy: prospective Single-Tertiary study. Inflamm Bowel Dis 2021. 10.1093/ibd/izab301. [Epub ahead of print: 29 Nov 2021].</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ibd/izab301</ArticleId><ArticleId IdType="pubmed">34849919</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander JL, Kennedy NA, Ibraheim H, et al. . COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. Lancet Gastroenterol Hepatol 2022;7:342&#x2013;52. 10.1016/S2468-1253(22)00005-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(22)00005-X</ArticleId><ArticleId IdType="pmc">PMC8813209</ArticleId><ArticleId IdType="pubmed">35123676</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakuraba A, Luna A, Micic D. Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis. Gastroenterology 2022;162:88&#x2013;108. 10.1053/j.gastro.2021.09.055</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2021.09.055</ArticleId><ArticleId IdType="pmc">PMC8479970</ArticleId><ArticleId IdType="pubmed">34599933</ArticleId></ArticleIdList></Reference><Reference><Citation>Volkers A, Wieske L, van Dam K, et al. . DOP27 Humoral immune response after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases treated with immunosuppressive therapy - a Target to B! study. J Crohns Colitis 2022;16:i079. 10.1093/ecco-jcc/jjab232.066</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecco-jcc/jjab232.066</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebinger JE, Fert-Bober J, Printsev I, et al. . Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med 2021;27:981&#x2013;4. 10.1038/s41591-021-01325-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01325-6</ArticleId><ArticleId IdType="pmc">PMC8205849</ArticleId><ArticleId IdType="pubmed">33795870</ArticleId></ArticleIdList></Reference><Reference><Citation>Prendecki M, Clarke C, Edwards H, et al. . Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. Ann Rheum Dis 2021;80:1322&#x2013;9. 10.1136/annrheumdis-2021-220626</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220626</ArticleId><ArticleId IdType="pmc">PMC8350975</ArticleId><ArticleId IdType="pubmed">34362747</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy NA, Lin S, Goodhand JR, et al. . Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut 2021;70:1884&#x2013;93. 10.1136/gutjnl-2021-324789</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324789</ArticleId><ArticleId IdType="pubmed">33903149</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch M, Krammer F, Regev-Yochay G, et al. . SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nat Rev Immunol 2022;22:57&#x2013;65. 10.1038/s41577-021-00662-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00662-4</ArticleId><ArticleId IdType="pmc">PMC8649989</ArticleId><ArticleId IdType="pubmed">34876702</ArticleId></ArticleIdList></Reference><Reference><Citation>
Wei J, Pouwels KB, Stoesser N. SARS-CoV-2 anti-spike IgG antibody responses after second dose of ChAdOx1 or BNT162b2 and correlates of protection in the UK general population [Internet]. bioRxiv
2021. 
http://medrxiv.org/lookup/doi/10.1101/2021.09.13.21263487
</Citation></Reference><Reference><Citation>Levin EG, Lustig Y, Cohen C, et al. . Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med 2021;385:e84. 10.1056/NEJMoa2114583</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2114583</ArticleId><ArticleId IdType="pmc">PMC8522797</ArticleId><ArticleId IdType="pubmed">34614326</ArticleId></ArticleIdList></Reference><Reference><Citation>Charilaou P, Tricarico C, Battat R, et al. . Impact of inflammatory bowel disease therapies on durability of humoral response to SARS-CoV-2 vaccination. Clin Gastroenterol Hepatol 2021. 10.1016/j.cgh.2021.12.007. [Epub ahead of print: 09 Dec 2021].</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2021.12.007</ArticleId><ArticleId IdType="pmc">PMC8654702</ArticleId><ArticleId IdType="pubmed">34896283</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan N, Mahmud N. Effectiveness of SARS-CoV-2 vaccination in a Veterans Affairs cohort of patients with inflammatory bowel disease with diverse exposure to immunosuppressive medications. Gastroenterology 2021;161:827&#x2013;36. 10.1053/j.gastro.2021.05.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2021.05.044</ArticleId><ArticleId IdType="pmc">PMC8146263</ArticleId><ArticleId IdType="pubmed">34048782</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, et al. . Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603&#x2013;15. 10.1056/NEJMoa2034577</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, et al. . Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403&#x2013;16. 10.1056/NEJMoa2035389</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Lev-Tzion R, Focht G, Lujan R, et al. . COVID-19 vaccine is effective in inflammatory bowel disease patients and is not associated with disease exacerbation. Clin Gastroenterol Hepatol 2021. 10.1016/j.cgh.2021.12.026. [Epub ahead of print: 23 Dec 2021].</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2021.12.026</ArticleId><ArticleId IdType="pmc">PMC8697416</ArticleId><ArticleId IdType="pubmed">34954338</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadi YB, Thakkar S, Shah-Khan SM, et al. . COVID-19 Vaccination Is Safe and Effective in Patients With Inflammatory Bowel Disease: Analysis of a Large Multi-institutional Research Network in the United States. Gastroenterology 2021;161:1336&#x2013;9. 10.1053/j.gastro.2021.06.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2021.06.014</ArticleId><ArticleId IdType="pmc">PMC8205252</ArticleId><ArticleId IdType="pubmed">34144044</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization , 2021. Available: https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern
</Citation></Reference><Reference><Citation>Ai J, Zhang H, Zhang Y, et al. . Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg Microbes Infect 2022;11:337&#x2013;43. 10.1080/22221751.2021.2022440</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.2022440</ArticleId><ArticleId IdType="pmc">PMC8788341</ArticleId><ArticleId IdType="pubmed">34935594</ArticleId></ArticleIdList></Reference><Reference><Citation>
Zhou H, Tada T, Dcosta BM. SARS-CoV-2 Omicron BA.2 Variant Evades Neutralization by Therapeutic Monoclonal Antibodies [Internet]. bioRxiv
2022. 
https://www.biorxiv.org/content/10.1101/2022.02.15.480166v1
</Citation></Reference><Reference><Citation>
Schell TL, Knutson KL, Saha S. Humoral immunogenicity of three COVID-19 mRNA vaccine doses in patients with inflammatory bowel disease [Internet]. bioRxiv
2021. 
http://medrxiv.org/lookup/doi/10.1101/2021.12.22.21268217
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047192</ArticleId><ArticleId IdType="pubmed">35396992</ArticleId></ArticleIdList></Reference><Reference><Citation>
Quan J, Ma C, Panaccione R. Serological responses to the first three doses of SARS-CoV-2 vaccination in inflammatory bowel disease: A prospective cohort study [Internet]. bioRxiv
2022. 
http://medrxiv.org/lookup/doi/10.1101/2022.03.16.22272440
</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>
COVID-19 vaccines for moderately or severely immunocompromised people. Available: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html
</Citation></Reference><Reference><Citation>Shehab M, Abu-Farha M, Alrashed F, et al. . Immunogenicity of BNT162b2 vaccine in patients with inflammatory bowel disease on infliximab combination therapy: a multicenter prospective study. J Clin Med 2021;10:5362. 10.3390/jcm10225362</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10225362</ArticleId><ArticleId IdType="pmc">PMC8623980</ArticleId><ArticleId IdType="pubmed">34830644</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>